REC-1245
PreclinicalSmall molecule
REC-1245 is one of 10 small molecule programs targeting Cancers. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Cancers
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Mekinist
NovartisPhase 2
Gemzar
Johnson & JohnsonPhase 2
Gleevec
NovartisPhase 2
Tafinlar
NovartisPhase 2
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 2
Telisotuzumab Adizutecan
AbbViePhase 2
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Phase 2
Upifitamab Rilsodotin
MMersana Therapeutics
Phase 2
REC-1245
RRecursion Pharmaceuticals Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for REC-1245. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- RRecursion Pharmaceuticals Inc.